Sage Journals: Discover world-class research

Abstract

Treatment of relapsing-remitting multiple sclerosis (RRMS) with protein therapeutics such as interferon beta (IFNβ) frequently results in the development of binding antibodies (BAbs) to the administered agent. Neutralizing antibodies (NAbs) are a subset of BAbs characterized by their interference with IFNβ's biological target(s) and/or function(s). At the treatment group level, NAbs to IFNβ have been shown to have an impact on relapse rate and MRI disease measures. However, in individual patients, the clinical significance of NAbs remains controversial because of the lack of standardized assessment procedures, the absence of widely accepted cutoff values to distinguish NAb-positive from NAb-negative patients, and the high rate of seroconversion (to NAb-negative status) observed in clinical studies. At the recommended 44 μg tiw dose of IFNβ-1a subcutaneous (SC) (Rebif®), 12—14% of patients were persistently NAb-positive at two, three, and four years of treatment, while ~25% of anytime NAb-positive patients later became seronegative. Relapse rate and MRI measures of disease were higher in NAb-positive than NAb-negative patients; however, both demonstrated significant improvement versus placebo treatment or delayed treatment patients. Pending improved assessment methodology and better characterization of the clinical impact of NAbs, treatment decisions should continue to be based on the wide range of factors that determine clinical effectiveness. Multiple Sclerosis 2007; 13: S8—S13 http://msj.sagepub.com

Keywords

interferons multiple sclerosis neutralizing antibodies

Get full access to this article

View all access options for this article.

References

Goodin DS

Frohman EM

Garmany GP Jr

Halper J.

Likosky WH

Lublin FD

et al. Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology2002; 58: 169—78.

Panitch H.

Goodin D.

Francis G.

Chang P.

Coyle P.

O'Connor P.

et al. The EVIDENCE (Evidence of Interferon Dose-response: European North American Comparative Efficacy) Study Group and the University of British Columbia MS/MRI Research Group. Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trial. J Neurol Sci2005; 239: 67—74.

Galleta SL

Markowitz C.

Lee AG

Immunomodulatory agents for the treatment of relapsing multiple sclerosis: A systematic review. Arch Intern Med2002; 162: 2161—69.

Trapp BD

Peterson J.

Ransohoff RM

Rudick R.

Mork S.

Bo L.

Axonal transaction in the lesions of multiple sclerosis. N Engl J Med1998; 338: 278—85.

Lucchinetti C.

Bruck W.

Parisi J.

Scheithauer B.

Rodriquez M.

Lassman H.

Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol2000; 47: 707—17.

PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet1998; 352: 1498—504.

Jacobs LD

Cookfair DL

Rudick RA

Herndon RM

Richert JR

Salazar AM

et al. The Multiple Sclerosis Collaborative Research Group (MSCRG). Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol1996; 39: 285—94.

The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group.

Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology1995; 45: 1277—85.

BETASERON® (Interferon beta-1b) prescribing information. Berlex Laboratories, 2003.

10.

AVONEX® (Interferon beta-1a) prescribing information. Biogen IDEC Inc., 2005.

11.

REBIF ® (Interferon beta-1a) prescribing information. EMD Serono Inc., 2005.

12.

Schellekens H.

Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin Ther2002; 24: 1720—40; discussion 1719.

13.

Giovannoni G.

Munschauer FE

3rd, Deisenhammer F. Neutralising antibodies to interferon beta during the treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry2002; 73: 465—69.

14.

Giovannoni G.

Optimising MS disease-modifying therapies: Antibodies in perspective. J Neurol2004; 251(Suppl 5): v30—v35.

15.

Pachner A.

Narayan K.

Price N.

Hurd M.

Dail D.

MxA gene expression analysis as an interferon-beta bioactivity measurement in patients with multiple sclerosis and the identification of antibody-mediated decreased bioactivity. Mol Diagn2003; 7: 17—25.

16.

Wolinsky JS

Toyka KV

Kappos L.

Grossberg SE

Interferon-beta antibodies: Implications for the treatment of MS. Lancet Neurol2003; 2: 528.

17.

The Once Weekly Interferon for MS Study Group.

Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. Neurology1999; 53: 679—86.

18.

The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group.

Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology1996; 47: 889—94.

19.

Prisms-4.

Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology2001; 56: 1628—36.

20.

Panitch H.

Goodin DS

Francis G.

Chang P.

Coyle PK

O'Connor P.

et al. EVIDENCE (Evidence of Interferon Dose-response: European North American Compartative Efficacy) Study Group; The University of British Columbia MS/MRI Research Group. Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. Neurology2002; 59:1496—506.

21.

Freedman MS

Francis GS

Sanders EA

Rice GP

O'Connor P.

Comi G.

et al. Once Weekly Interferon beta-1alpha for Multiple Sclerosis Study Group; The University of British Columbia MS/MRI Research Group. Randomized study of once weekly interferon beta-1a therapy in relapsing multiple sclerosis: Three-year data from the OWIMS study. Mult Scler2005; 11: 41—45.

22.

Sandberg-Wollheim M.

Stam-Moraga M.

Alsop C.

Abdalla JA

The PRISMS (the Prevention of Relapses and Disability by Interferon-beta-1-a Subcutaneously in Multiple Sclerosis) Study — report on neutralising antibodies up to year 6 of treatment. Neurology2003; 60(Suppl 1): A482—83.

23.

Francis GS

Rice GP

Alsop JC

;

the PRISMS Study Group.

Interferon beta-1a in MS: Results following development of neutralizing antibodies in PRISMS . Neurology2005; 65: 48—55.

24.

EMD Serono, Inc. Data on file.

25.

Gneiss C.

Reindl M.

Lutterotti A.

Ehling R.

Egg R.

Khalil M.

et al. Interferon-beta: the neutralizing antibody (NAb) titre predicts reversion to NAb negativity. Mult Scler2004 ; 10: 507—10.

26.

Schwid SR

Thorpe J.

Sharief M.

Sandberg-Wollheim M.

Rammohan K.

Wendt J.

et al. EVIDENCE (Evidence of Interferon Dose-response: European North American Compartative Efficacy) Study Group; The University of British Columbia MS/MRI Research Group. Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: The EVIDENCE Study. Arch Neurol2005; 62: 785—92.

27.

Giovannoni G.

Barbarash OL

Jaber A.

King J.

Metz LM

Mitchell L.

et al. Reduced immunogenicity with a new formulation of interferon beta-1a (Rebif®): 24- and 48-week results of a phase IIIb study. Abstract P675. 22nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), 27—30 September 2006, Madrid, Spain.

Neutralizing antibodies in MS therapy: reviewing the Rebif experience

Abstract

Keywords

Get full access to this article

References